HomeProductsMaterials ScienceMOF LigandsNitrogen containing MOF ligandsRidinilazole
Chemical structure of CAS 308362-25-6

Ridinilazole

In Stock•Starting at $142 for 50 mg•Purity ≥ 98%
CAS No.308362-25-6
MDL No.MFCD28963972
MFC24H16N6
MW388.40
InChI KeyUHQFBTAJFNVZIV-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg98%$142In Stock
100 mg98%$236In Stock
250 mg98%$354In Stock
1 g98%$845In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.308362-25-6
Product NameRidinilazole

Associated Conditions

clostridium difficile infection·bacterial disease·infection
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.

The Journal of antimicrobial chemotherapy • Vol. 70, Issue 6 • 2015
PMID: 25652749PMC: PMC4498292DOI: 10.1093/jac/dkv005

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.

The Journal of antimicrobial chemotherapy • Vol. 70, Issue 6 • 2015
PMID: 25652750PMC: PMC4498293DOI: 10.1093/jac/dkv006

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.

The Journal of antimicrobial chemotherapy • Vol. 70, Issue 1 • 2015
PMID: 25190720PMC: PMC4267497DOI: 10.1093/jac/dku324

In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.

Antimicrobial agents and chemotherapy • Vol. 58, Issue 10 • 2014
PMID: 25022586PMC: PMC4187990DOI: 10.1128/AAC.02903-14

Documentation